These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12411786)

  • 41. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscles via activation of the ryanodine receptor Ca2+ channel.
    Tegazzin V; Scutari E; Treves S; Zorzato F
    Anesthesiology; 1996 Jun; 84(6):1380-5. PubMed ID: 8669679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Association between OXPHOS-Related Gene Expression and Malignant Hyperthermia Susceptibility in Human Skeletal Muscle Biopsies.
    Chang L; Motley R; Daly CL; Diggle CP; Hopkins PM; Shaw MA
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocyte-based determination of susceptibility to malignant hyperthermia: a pilot study in swine.
    Bina S; Capacchione J; Muldoon S; Bayarsaikhan M; Bunger R
    Anesthesiology; 2010 Oct; 113(4):917-24. PubMed ID: 20823761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
    Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
    Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is lymphocyte adenosine a diagnostic marker of clinical malignant hyperthermia? A pilot study.
    Bina S; Capacchione J; Munkhuu B; Muldoon S; Bünger R
    Crit Care Med; 2015 Mar; 43(3):584-93. PubMed ID: 25479114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
    Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
    Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intramuscular injection of malignant hyperthermia trigger agents induces hypermetabolism in susceptible and nonsusceptible individuals.
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2010 Jan; 27(1):77-82. PubMed ID: 19809329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
    Censier K; Urwyler A; Zorzato F; Treves S
    J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo whole-body resting energy expenditure and insulin action in human malignant hyperthermia.
    Freymond D; Dériaz O; Frascarolo P; Reiz S; Jéquier E; Urwyler A
    Anesthesiology; 2000 Jul; 93(1):39-47. PubMed ID: 10861144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of human cultured myotubes responses mediated by ryanodine receptor 1.
    Kobayashi M; Mukaida K; Migita T; Hamada H; Kawamoto M; Yuge O
    Anaesth Intensive Care; 2011 Mar; 39(2):252-61. PubMed ID: 21485675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.
    Rueffert H; Olthoff D; Deutrich C; Schober R; Froster UG
    Am J Med Genet A; 2004 Jan; 124A(3):248-54. PubMed ID: 14708096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.